

Appendix 2: Trials investigating nicotine gum (page 1 of 2)

Study	Sample size	Design	Country	Mean CPD	Smoking abstinence (%)							
					6 Months				12 Months			
					Point prevalence		Continuous		Point prevalence		Continuous	
					Active	Control	Active	Control	Active	Control	Active	Control
Campbell 1987 ¹	836	R, DB, PC, MC	England	22	NR	NR	NR	NR	5	3	NR	NR
Killen 1990* ²	610	R, DB, PC, MC	USA	25	NR	NR	NR	NR	19	18	NR	NR
Hughes 1989 ³	315	R, DB, PC, MC	USA	30	29	19	NR	NR	12	9	11	6
Garvey 2000 ii*† ⁴	406	R, DB, PC	USA	24	22	11	NR	NR	20	8	13	9
Garvey 2000 i*† ⁴	405	R, DB, PC	USA	23	27	11	NR	NR	17	8	13	9
Fee 1982 ⁵	352	R, DB, PC	England	NR	13	14	NR	NR	13	9	NR	NR
Fortmann 1988*‡ ⁶	300	R, DB, PC	USA	25	22	30	NR	NR	NR	NR	NR	NR
Cooper 2005 ⁷	294	R, DB, PC	USA	23	12	11	NR	NR	12	10	NR	NR
Hjalmarson 1984 ⁸	206	R, DB, PC	Sweden	24	NR	NR	35	20	NR	NR	27	16
Jamrozik 1984 ⁹	200	R, DB, PC, MC	England	NR	10	8	NR	NR	NR	NR	NR	NR
Areechon 1988 ¹⁰	199	R, DB, PC	Thailand	24	57	37	NR	NR	NR	NR	NR	NR
Hall 1996 ¹¹	201	R, DB, PC	USA	24	31	30	NR	NR	24	27	21	24
Blondal 1989 ¹²	182	R, DB, PC	Iceland	NR	NR	NR	NR	NR	40	27	33	24
Herrera 1995* ¹³	154	R, DB, PC, MC	Sweden & Venezuela	16	NR	NR	53	26	NR	NR	44	19
Malcolm 1980 ¹⁴	136	R, DB, PC	England	26	NR	NR	23	5	NR	NR	NR	NR
Tonnesen 1988* ¹⁵	113	R, DB, PC	Denmark	20	NR	NR	NR	NR	NR	NR	38	27
Jarvis 1982 ¹⁶	116	R, DB, PC	USA	29	NR	NR	NR	NR	47	21	31	14
Schneider 1983§ ¹⁷	96	R, DB, PC	USA	NR	NR	NR	37	19	NR	NR	23	17
Hall 1987 ii*¶ ¹⁸	70	R, DB, PC	USA	30	56	35	NR	NR	50	21	NR	NR
Hall 1987 i*¶ ¹⁸	69	R, DB, PC	USA	30	43	21	NR	NR	35	21	NR	NR
Jarvik 1984 ¹⁹	48	R, DB, PC, MC	USA	NR	NR	NR	NR	NR	28	17	NR	NR

CPD = cigarettes per day, R = randomized, DB = double-blind, PC = placebo controlled, MC = multi-center, NR = not reported.

References appear on the next page.

*Number of subjects included in the analysis: participants who were from centres that did not biochemically validate abstinence claims, not randomized to either an add lib nicotine gum or placebo, received more than one pharmacotherapy or medications other than those included in our study, or participated in an open label arm of the study were excluded from our analyses.

†The RCT by Garvey et al. had 3 treatment arms: 2 mg nicotine gum (ii), 4 mg nicotine gum (i), and placebo.

‡Preliminary report of Killen 1990.

§The 1995 RCT by Schneider et al. did not report dosage and was thus excluded from our analyses and forest plot.

¶The RCT by Hall et al. used a factorial design, randomizing patients to high- or low-intensity behavioural therapy and nicotine gum or placebo. We compare nicotine gum with low-intensity therapy versus placebo with low-intensity behavioural therapy (ii) and nicotine gum with intensive therapy versus placebo with intensive therapy (i).

References to Appendix 2 (page 2 of 2)

1. Campbell IA, Lyons E, Prescott RJ. Stopping smoking. Do nicotine chewing-gum and postal encouragement add to doctors' advice. *Practitioner* 1987;231:114-7.
2. Killen JD, Fortmann SP, Newman B, et al. Evaluation of a treatment approach combining nicotine gum with self-guided behavioral treatments for smoking relapse prevention. *J Consult Clin Psychol* 1990;58:85-92.
3. Hughes JR, Gust SW, Keenan RM, et al. Nicotine vs placebo gum in general medical practice. *JAMA* 1989;261:1300-5.
4. Garvey AJ, Kinnunen T, Nordstrom BL, et al. Effects of nicotine gum dose by level of nicotine dependence. *Nicotine Tob Res* 2000;2:53-63.
5. Fee WM, Stewart MJ. A controlled trial of nicotine chewing gum in a smoking withdrawal clinic. *Practitioner* 1982;226:148-51.
6. Fortmann SP, Killen JD, Telch MJ, et al. Minimal contact treatment for smoking cessation. A placebo controlled trial of nicotine polacrilex and self-directed relapse prevention: initial results of the Stanford Stop Smoking Project. *JAMA* 1988;260:1575-80.
7. Cooper TV, Klesges RC, Debon MW, et al. A placebo controlled randomized trial of the effects of phenylpropanolamine and nicotine gum on cessation rates and postcessation weight gain in women. *Addict Behav* 2005;30:61-75.
8. Hjalmarsson AI. Effect of nicotine chewing gum in smoking cessation. A randomized, placebo-controlled, double-blind study. *JAMA* 1984;252:2835-8.
9. Jamrozik K, Fowler G, Vessey M, et al. Placebo controlled trial of nicotine chewing gum in general practice. *Br Med J (Clin Res Ed)* 1984;289:794-7.
10. Areechon W, Punnotok J. Smoking cessation through the use of nicotine chewing gum: a double-blind trial in Thailand. *Clin Ther* 1988;10:183-6.
11. Hall SM, Munoz RF, Reus VI, et al. Mood management and nicotine gum in smoking treatment: a therapeutic contact and placebo-controlled study. *J Consult Clin Psychol* 1996;64:1003-9.
12. Blondal T. Controlled trial of nicotine polacrilex gum with supportive measures. *Arch Intern Med* 1989;149:1818-21.
13. Herrera N, Franco R, Herrera L, et al. Nicotine gum, 2 and 4 mg, for nicotine dependence. A double-blind placebo-controlled trial within a behavior modification support program. *Chest* 1995;108:447-51.
14. Malcolm RE, Sillett RW, Turner JA, et al. The use of nicotine chewing gum as an aid to stopping smoking. *Psychopharmacology (Berl)* 1980;70:295-6.
15. Tonnesen P, Fryd V, Hansen M, et al. Effect of nicotine chewing gum in combination with group counseling on the cessation of smoking. *N Engl J Med* 1988;318:15-8.
16. Jarvis MJ, Raw M, Russell MA, et al. Randomised controlled trial of nicotine chewing-gum. *Br Med J (Clin Res Ed)* 1982;285:537-40.
17. Schneider NG, Jarvik ME, Forsythe AB, et al. Nicotine gum in smoking cessation: a placebo-controlled, double-blind trial. *Addict Behav* 1983;8:253-61.
18. Hall SM, Tunstall CD, Ginsberg D, et al. Nicotine gum and behavioral treatment: a placebo controlled trial. *J Consult Clin Psychol* 1987;55:603-5.
19. Jarvik ME, Schneider NG. Degree of addiction and effectiveness of nicotine gum therapy for smoking. *Am J Psychiatry* 1984;141:790-1.